期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
雌二醇共晶的研究 被引量:2
1
作者 郭爱鑫 巩孝芳 +6 位作者 何佳璘 郭一鸣 宁丽峰 陈晓锋 徐娟 郭颖志 王慧萍 《医药导报》 CAS 北大核心 2021年第12期1716-1723,共8页
目的研究雌激素雌二醇的共晶现象,筛选其共晶化合物并进行初步评价,以改善药物的理化性质。方法经过结构设计选取能与雌二醇形成共晶体的配合物;通过蒸发结晶法、降温析晶法、研磨法、混悬液法等制备新共晶;共晶的鉴别表征采用单晶X射... 目的研究雌激素雌二醇的共晶现象,筛选其共晶化合物并进行初步评价,以改善药物的理化性质。方法经过结构设计选取能与雌二醇形成共晶体的配合物;通过蒸发结晶法、降温析晶法、研磨法、混悬液法等制备新共晶;共晶的鉴别表征采用单晶X射线衍射分析法、粉末X射线衍射分析法(PXRD)、热重-差示扫描量热法(TG-DSC)、红外光谱法等;并对共晶样品的稳定性、溶解性进行分析。结果用蒸发结晶方法获得雌二醇-尿素共晶(共晶Ⅰ),雌二醇-乙酰胺共晶(共晶Ⅱ)并制备成单晶,表征分析结果显示PXRD、磁共振(NMR)、TG-DSC、熔点法均可表征共晶和药物活性成分(API)以及两种共晶之间的不同,单晶X射线衍射结果显示两种共晶分子比例分别为1:1,4:4。两种共晶在高温、高湿、光照条件下稳定。两种共晶在6种溶出介质中溶出行为一致。在pH值1.2盐酸缓冲溶液中,共晶Ⅱ的累计溶出度比原料药的大近2倍,比共晶Ⅰ大1.2倍,且共晶Ⅱ的溶出速率高于共晶Ⅰ。结论以雌二醇为API进行共晶筛选,共获得共晶Ⅰ和共晶Ⅱ两种药物共晶,其中共晶Ⅱ为首次发现的雌二醇新的共晶。新获得的共晶样品与雌二醇原料药晶型比较同样稳定,但溶出速率增加。共晶Ⅱ为优势晶型。 展开更多
关键词 雌二醇 药物共晶 稳定性 溶解性 药物活性成分 共晶形成物 优势晶型
下载PDF
炔雌醇共晶药动学研究
2
作者 宁丽峰 杜荣凯 +1 位作者 张雷 徐娟 《医药导报》 CAS 北大核心 2022年第3期283-286,共4页
目的研究炔雌醇4种共晶(炔雌醇-哌嗪、炔雌醇-烟酰胺、炔雌醇-川芎嗪、炔雌醇-咪唑)在大鼠体内的吸收与代谢,探讨炔雌醇共晶药动学研究方法。方法雌性SD大鼠口服给药,剂量为5.0 mg·kg^(-1)(炔雌醇相当量),于规定时间分批取血。结... 目的研究炔雌醇4种共晶(炔雌醇-哌嗪、炔雌醇-烟酰胺、炔雌醇-川芎嗪、炔雌醇-咪唑)在大鼠体内的吸收与代谢,探讨炔雌醇共晶药动学研究方法。方法雌性SD大鼠口服给药,剂量为5.0 mg·kg^(-1)(炔雌醇相当量),于规定时间分批取血。结果炔雌醇达峰时间1 h,于24 h内代谢完毕;4种共晶达峰时间约为1.5 h,于48 h内代谢完毕;炔雌醇血药浓度-时间曲线下面积(AUC)为(25.1±2.8)h·ng·mL^(-1),炔雌醇-哌嗪共晶AUC(28.3±1.5)h·ng·mL^(-1),炔雌醇-烟酰胺共晶AUC(26.8±2.2)h·ng·mL^(-1),炔雌醇-川芎嗪共晶AUC(24.2±4.4)h·ng·mL^(-1),炔雌醇-咪唑共晶AUC(23.6±2.5)h·ng·mL^(-1)。结论炔雌醇形成共晶后,药物释放时间延长;通过制备炔雌醇-哌嗪共晶和炔雌醇-烟酰胺共晶可提高炔雌醇在大鼠体内的生物利用度。 展开更多
关键词 炔雌醇共晶 药动学 血药浓度-时间曲线下面积
下载PDF
C-terminal domain of Chk1 regulates its subcellular location and kinase activity for DNA repair 被引量:1
3
作者 ning lifeng WANG HuiPing +1 位作者 SAN Dan SANG JianLi 《Chinese Science Bulletin》 SCIE EI CAS 2011年第30期3138-3147,共10页
Effector kinase Chk1 is an evolutionarily conserved protein kinase. It is a key mediator linking the mechanisms that monitor DNA integrity to components of the cell cycle engine. In this study, recombinant vectors pEG... Effector kinase Chk1 is an evolutionarily conserved protein kinase. It is a key mediator linking the mechanisms that monitor DNA integrity to components of the cell cycle engine. In this study, recombinant vectors pEGFP-C1-Chk1/C 288/C 334/C 368 were constructed and transfected into HeLa cells to study the effect of the Chk1 regulatory domain on the regulation of subcellular Chk1 location in response to DNA damage. We found that DNA damage-induced nuclear accumulation is regulated by 34 amino acids (334–368) in the C-terminal regulatory domain. Recombinant vectors pXJ41-Chk1/C 288/C 334/C 368 were co-transfected with reporter plasmid pEGFP-N2 into HeLa cells to study the repair abilities of the different human Chk1 truncation mutants. In addition, recombinant vectors were transfected into HeLa cells to study the effects of the different truncation mutants on the cell cycle. Furthermore, to study the kinase activity of the different truncation mutants, Ser216 phosphorylation of Cdc25C was studied by Western blot analysis. We found that the enzymatic activity of C 368, missing the 108 C-terminal amino acids (368–476), was higher than that of full-length Chk1, and C 368 delayed the cell cycle progression. The enzymatic activity of C 334, missing the 142 C-terminal amino acids (334–476), was equivalent to that of full-length Chk1. C 288, missing the 188 C-terminal amino acids (288–476), had almost no enzymatic activity, suggesting that the regulatory domain contains both inhibitory and regulatory elements. This study provides useful information for further research on Chk1 function. 展开更多
关键词 亚细胞定位 激酶活性 DNA修复 HELA细胞 DNA损伤 细胞周期 重组载体 BLOT分析
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部